Prospective Non-Interventional Observational Study of Use of Triumeq and Corresponding Monitoring Measures in Clinical Practice in Germany
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 27 Oct 2017
At a glance
- Drugs Abacavir/dolutegravir/lamivudine (Primary)
- Indications HIV infections
- Focus Adverse reactions
- Acronyms TRIUMPH
- Sponsors ViiV Healthcare
- 27 Oct 2017 First interim results (n=392; data cut off: 31 Dec 2016) presented at the 16th European AIDS Conference.
- 26 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 07 Aug 2017 Planned End Date changed from 1 Oct 2018 to 15 Oct 2018.